Efficacy and Safety of Jaktinib in Patients With COVID-19 Pneumonia.

Efficacy and Safety of Jaktinib in Patients With COVID-19 Pneumonia.

This was a randomized, double-blind, placebo-controlled parallel study.

Inclusion Criteria:

• 18 years of age, male or female;
• History of COVID-19 infection within 1 week;
• Subjects with HRCT consistent with viral pneumonia (Judged by investigator) and meeting any of the following criteria: With fever, respiratory symptoms; Shortness of breath present,RR ≥30 breaths/min.
• Clear consciousness, Capable and voluntary informed consent.

Exclusion Criteria:

• Unable to take tablets orally Or suspected hypersensitivity to Jaktinib, drugs of the same class, or their excipients, Patients with severe gastrointestinal dysfunction affecting drug absorption;
• Any person meeting criteria for critical pneumonia;
• Patients considered unsuitable for this trial by the investigator.